What differences or similarities do you think there are between problems in use by people with cancer pain versus non-malignant pain?
Please tell me about a case where you think problems from opioids outweighed the benefits for an individual patient. o
Please tell me about a case where you thought the balance between problems and benefits from opioids was equivocal for an individual patient. o
Please tell me about a case where you thought potential problems from opioids were successfully managed to enable greater net benefit for an individual patient.
SECTION 3: FURTHER EXPLORATION OF
The following topics will be of specific interest to explore where they are broached during discussion in Section 1 or 2.
1. Concept of problematic use or 'misuse' in cancer (using non-malignant pain as a comparator where necessary to elucidate)
Sample starter question:
Are you comfortable with the term 'misuse' being applied to opioid use in the cancer context, or do you think the context differs sufficiently from non-malignant pain to make this term less useful?
o Prompts (based on TGA's consultation paper outcomes/drivers): 1 • Risk of overdose resulting in morbidity or mortality • Risk of tolerance, requiring higher doses of product being required to achieve analgesia, but with accompanying increases in adverse effects (including potential addiction) • Risk of addiction, including following tolerance and through use at prescribed rather than excessive levels • Risk of deliberate abuse, encompassing use of high doses of immediate release opioids and manipulation of 'abuse deterrent' dose forms • Risk of overuse or inappropriate use • Risk of diversion of legally-prescribed product to others for abuse purposes. 22 • Attitudes towards opioids (vis-à-vis other strategies) • Subjective norm o Other factors:
• Prompts/examples (based on the non-malignant pain literature): [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] • Perception of the current zeitgeist 'pendulum' regarding prioritising prevention of problematic use versus pain control • Concerns about potential sanctions for 'doing the wrong thing' (e.g. legal or professional) • Prompts (based on Rasich's model of factors influencing prescribing decisions) 22 • Direct methods (e.g. prescribing restrictions, financial incentives, medical management protocols) • Practice factors (e.g. demographics, organisational structure) • Indirect methods (e.g. advertisements/drugs salesmen, colleagues, medical school education, continuing education).
Managing risk of problematic use in people with cancer prescribed opioids
Sample starter question: 
